<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057030</url>
  </required_header>
  <id_info>
    <org_study_id>CN156-038</org_study_id>
    <nct_id>NCT01057030</nct_id>
  </id_info>
  <brief_title>Multiple Dose Japanese Bridging Study</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of multiple oral daily
      doses of BMS-708163 in healthy young male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMS-708163 or placebo in Japanese and non-Japanese: Safety and tolerability (AE's, ECG, vital signs, safety labs)</measure>
    <time_frame>Every day for 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMS-708163 pharmacokinetic parameters (Cmax, Cmin, Ctrough, Tmax, AUC(TAU), AI, and CLT/F and T-HALF (only following Day 14 dose))</measure>
    <time_frame>Days 1, 7, and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>A1 (BMS-708163)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy Japanese Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy Japanese Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 (BMS-708163)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy Non-Japanese Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy Non-Japanese Subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-708163</intervention_name>
    <description>Capsules, Oral, 125 mg, once daily, 14 days</description>
    <arm_group_label>A1 (BMS-708163)</arm_group_label>
    <arm_group_label>B1 (BMS-708163)</arm_group_label>
    <other_name>(GAMMA SECRETASE inhibitor)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, Oral, 0 mg, once daily, 14 days</description>
    <arm_group_label>A2 (Placebo)</arm_group_label>
    <arm_group_label>B2 (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese and non-Japanese subjects

          -  Japanese subjects must be first generation Japanese and must demonstrate both maternal
             and paternal Japanese ancestry

          -  Non-Japanese subjects must not be of Japanese or Asian descent, ie, neither parent nor
             grandparent was born in Japan or in any Asian country

          -  BMI of 19 to 25 kg/m², for Japanese and non-Japanese subjects

          -  Men ages 20 to 45 years

        Exclusion Criteria:

          -  Serum creatinine values above the normal range

          -  Urine protein or blood levels above the normal range

          -  Liver function tests above the normal range

          -  TSH, free T3, or free T4 outside the normal range

          -  Amylase or lipase levels above the normal range

          -  Positive Fecal Immunochemical Test (FIT™)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

